ASIC Corporations (Exposure Period) Instrument 2026/90

The instrument is built around a small set of legal concepts drawn directly from the Act and its market architecture. These are:

• Exposure period: The instrument defines exposure period in relation to a disclosure document being supplemented or replaced as “the period mentioned in subsection 727(3) of the Act in relation to the disclosure document (including the period as extended by ASIC under that subsection)” (s 6). That definition imports the Act’s exposure-period mechanics and ASIC’s power to extend that period.

• Updating document: The instrument uses the term “updating document” to mean a supplementary or replacement document lodged under s 719 of the Act (s 7 heading and text). The instrument’s relief is specifically tied to lodgement of these updating documents.

• Subsection 727(3) relief: Sections 7-9 operate by creating exemptions from the operation of s 727(3) of the Act. The instrument does not repeal s 727(3) or alter its text; it provides circumstances where compliance with that subsection is not required to the extent it would otherwise prohibit dealing specified in the instrument (ss 7-9).

• Quoted securities and declared financial market: Sections 8 and 9 provide “to avoid doubt” exemptions where securities, or the underlying securities for options, are in a class that is quoted on a declared financial market at the time of lodgement of the disclosure document. The instrument points to the Act for the definition of “declared financial market” (Note under s 8), and references a transitional rule (s 1705F) that treats previously prescribed markets as declared until the first declaration under s 9D is made.

• PDS and product trading status: Section 10 addresses PDS-driven applications for managed investment products and retail CCIV securities. It disapplies subsection 1016B(1) for responsible persons where, at the time of lodgement of the PDS, the product is in a class “able to be traded on a declared financial market.” Section 10(2) makes explicit that a current suspension of trading does not negate the class’s status for the exemption.

• Temporal limits and repeal: The instrument is temporary in force; commencement is staged (s 2) and the instrument is repealed at the start of 1 April 2031 (s 11). The instrument also expressly repeals a prior ASIC exposure-period instrument (Schedule 1).

Conceptually, the instrument is not an omnibus amendment to the Act. It functions by specifying limited disapplications of exposure-period prohibitions where the market status of the securities/products (quoted or tradable on declared markets) or the timing of updating-document lodgement changes the practicalities of disclosure and subscription. The instrument therefore rests on the legal mechanism of delegated exemption rather than statutory amendment.

This instrument creates legal effects for a narrow set of market participants and for investors who interact with those participants:

• Issuers and offerors of securities who lodge disclosure documents and later lodge supplementary or replacement documents. Section 7 directly affects any person lodging an updating document under s 719 of the Act by altering the situations in which subsection 727(3) must be complied with. That will include companies and other entities making offers where a prospectus or other disclosure document is updated or replaced.

• Sellers or transferors and those accepting applications for securities offered under updating documents. Section 7 creates windows in which acceptance of applications, and the issuance or transfer of securities, may occur despite what subsection 727(3) would otherwise prohibit. The text applies to “a person who lodges an updating document” and removes the relevant prohibition “to the extent it would otherwise prohibit the person from accepting an application for, or issuing or transferring, securities offered under the updating document” (s 7(1)-(2)). That syntactic framing focuses the immediate beneficiary on the lodger of the updating document but the operative effect naturally extends to counterparties who would otherwise participate in offers or transfers.

• Issuers of quoted securities and persons offering options over quoted securities. Sections 8 and 9 expressly free such offers from the reach of subsection 727(3) at the time of lodgement of the disclosure document, where the relevant securities or underlying securities are in a class that is quoted on a declared financial market. The instrument’s note ties the class status to the declared financial market concept in the Act (s 8 note). Market-listed issuers and those making secondary offers in quoted classes will commonly fall within this category.

• Responsible persons of managed investment schemes and retail corporate collective investment vehicles (retail CCIVs). Section 10 relieves a responsible person from complying with subsection 1016B(1) for applications made in response to a PDS where the product is in a class able to be traded on a declared financial market at PDS lodgement. This affects fund managers, trustees, and responsible entities who prepare PDSs and handle applications.

• Investors and applicants. While the instrument’s text disapplies certain prohibitions that would otherwise restrict dealing, the affected investors are those who apply for or receive securities or products during the windows the instrument creates. The instrument does not itself create new investor protections; it modifies the timing-regime that would otherwise operate under the Act.

• ASIC and regulators. ASIC is the instrument-maker (s 3) and retains the underlying regulatory architecture; the instrument references ASIC’s power to extend exposure periods (s 6 definition). ASIC’s enforcement and interpretive role is indirectly affected because the exemptions change when subsection 727(3) or subsection 1016B(1) apply.

• Market operators. Operators of declared financial markets are indirectly implicated because the instrument’s relief hinges on the quoted or tradable status of a class on a declared financial market (s 8 and s 10). The instrument notes transitional arrangements for declared markets (s 8 note referencing s 9D and s 1705F).

Who does not benefit: the instrument does not change other disclosure obligations, continuous disclosure duties, prospectus content obligations, or licensing requirements in the Act. Its scope is limited to disapplying particular exposure-period prohibitions and does not create exemptions beyond those expressly stated (see ss 7-10 and s 7(3) preserving s 727(3) as to the original disclosure document).

The instrument alters the operation of a small set of statutory duties and rights by specifying when compliance with particular subsections of the Act is not required. It is important to read the instrument alongside the Act because it disapplies, rather than replaces, the statutory duties.

• Duty to comply with subsection 727(3): Subsections 7-9 operate by removing the need to comply with subsection 727(3) in particular circumstances. That is, the instrument says a person “does not have to comply with subsection 727(3) of the Act” in defined situations (s 7(1)-(2); s 8; s 9). The practical effect is that the statutory prohibition on accepting applications for, issuing, or transferring securities during the exposure period does not operate in those specific cases. The instrument does not alter what subsection 727(3) prohibits in other contexts, nor does it change the text of s 727(3).

• Rights to accept applications and to issue or transfer securities under an updating document: Section 7 confers practical rights , or at least removes prohibitions , allowing the person lodging the updating document to accept applications and to issue or transfer securities in the windows described. Those windows are concrete: where an updating document is lodged after the exposure period, dealing is permitted until seven days after lodgement (s 7(1)); where lodged before the expiry of the exposure period, dealing is permitted after the exposure period ends (s 7(2)). These rights derive from the statutory disapplication in the instrument.

• Right to make offers of quoted securities or options on quoted securities without complying with subsection 727(3): Sections 8 and 9 remove the need to comply with subsection 727(3) for offers of quoted securities or options where the relevant class is quoted at lodgement. That creates operational certainty for offers involving listed classes: the statutory exposure-period-bar need not be factored into timing decisions in those situations.

• Duty to comply with subsection 1016B(1): Section 10 removes the requirement for responsible persons to comply with subsection 1016B(1) in specified circumstances for PDS-driven applications. The precise duty in s 1016B(1) is not restated in the instrument; the instrument’s effect is confined to saying the responsible person “does not have to comply” with that subsection in the narrow circumstances described (s 10(1)).

• Preservation of application of s 727(3) to original disclosure documents: Section 7(3) explicitly states that the section “does not affect the application of subsection 727(3) of the Act to the disclosure document that is being supplemented or replaced.” This means the exemptions created by s 7 are limited in scope and do not provide blanket immunity from exposure-period rules that apply directly to the primary disclosure document.

• Temporal limits on these rights: The instrument commences on the later of registration and 1 April 2026 (s 2) and will be repealed at the start of 1 April 2031 (s 11). Rights under the instrument therefore exist only for the instrument’s currency.

• Delegated-law provenance and hierarchy: The instrument is made under subsections 741(1) and 1020F(1) of the Act (s 3). The instrument’s rights and disapplications are therefore subordinate to the Act; if any inconsistency arose, the Act would prevail.

The instrument does not create new disclosure content obligations, nor does it confer any new civil or criminal penalties. It simply changes the timing of when the specified statutory prohibitions apply (see ss 7-10). Practitioners must therefore treat the instrument as modifying discrete procedural timing duties without altering substantive disclosure content duties set out in other parts of the Act.

The instrument itself does not create new offences, penalties, or adjudicative mechanisms. It is an exemption instrument that expressly states where compliance with particular subsections of the Act is not required (see ss 7-10). Consequential enforcement points flow from that structure:

• No express penalties in the instrument: Nowhere in the instrument are new penalties or enforcement procedures created. The instrument simply relieves certain persons from having to comply with subsection 727(3) and subsection 1016B(1) in specified circumstances. Any contraventions or enforcement action therefore remain governed by the Corporations Act and its enforcement regime (the instrument is made under the Act, s 3).

• Enforcement remains under the Act: Because the instrument operates by disapplication of specified subsections, enforcement of disclosure obligations and related offences remains with the regimes established by the Act. For example, if a person acts outside the scope of the exemptions provided (i.e., where the person cannot properly rely on the instrument’s disapplication), that person may be exposed to the statutory consequences and enforcement actions under the Act for non-compliance with disclosure and offering rules. The instrument does not expand ASIC’s enforcement powers; it is made under ASIC’s instrument-making powers specified in subsections 741(1) and 1020F(1) (s 3).

• Administrative risk if the factual predicates are wrong: Reliance on the instrument requires the factual conditions set out in ss 7-10. If a person incorrectly treats a class as quoted or a product as able to be traded on a declared financial market at lodgement, or misapplies the timing rules for updating documents, that misreliance may expose the person to enforcement under the Act for contravening the relevant subsection (for example, s 727(3) or s 1016B(1)) if disapplication does not correctly apply. The instrument does not provide a safe-harbour certification mechanism; it simply articulates the circumstances for disapplication.

• ASIC’s contextual role: The instrument explicitly refers to ASIC’s power to extend the exposure period under subsection 727(3) as relevant to the definition of exposure period (s 6). That means ASIC’s administrative exercise of extension powers can change whether the instrument’s timing conditions are met, and ASIC’s decisions in that space remain enforceable and reviewable under the Act’s administrative law architecture (the instrument does not change ASIC’s powers).

• Repeal and temporal enforcement window: The instrument’s scheduled repeal at the start of 1 April 2031 (s 11) means its exemptions will cease to apply after that date unless replaced. Any transactions occurring after repeal cannot rely on the instrument.

In short, the instrument does not add penalty provisions; it adjusts which statutory prohibitions apply. Enforcement and penalties remain those established in the Corporations Act. The principal enforcement risk is misreliance on the instrument’s factual predicates, which would leave the market participant exposed to the ordinary machinery of civil or administrative enforcement under the Act.

The instrument operates as a delegated legislative instrument under authority granted in the Corporations Act and is expressly framed to interact with particular parts of the Act. Its interaction with other laws is therefore largely about how it disapplies specified statutory prohibitions. Key interaction points identified in the instrument are:

• Direct interaction with the Corporations Act subsections: The instrument is made under subsections 741(1) and 1020F(1) of the Act (s 3) and explicitly disapplies particular subsections of the Act , subsection 727(3) in ss 7-9 and subsection 1016B(1) in s 10. That is the instrument’s primary legal interaction; it modifies the application of these provisions for defined factual circumstances.

• Declared financial market concept and transitional rules: Sections 8 and 10 reference the declared financial market concept in the Act. The instrument’s note under s 8 explains that “declared financial market” is defined in s 9D of the Act and that, until the first declaration under s 9D(2), previously prescribed markets are treated as declared by virtue of s 1705F. This cross-reference means the instrument’s exemptions depend on the Act’s market-declaration framework and any transitional arrangements set out in the Act.

• Interaction with ASIC’s powers to extend exposure periods: The instrument’s definition of exposure period imports subsection 727(3) “including the period as extended by ASIC under that subsection” (s 6). ASIC’s administrative exercise to extend an exposure period therefore affects whether and when the instrument’s s 7 relief is available.

• No stated effect on other Act provisions: The instrument expressly preserves operation of subsection 727(3) in relation to the original disclosure document being supplemented or replaced (s 7(3)), demonstrating a limited disapplication rather than a wider repeal. The instrument does not state that it alters continuous disclosure obligations, prospectus content obligations, licensing requirements under the Act, or other statutory duties. Those obligations therefore continue to apply unchanged.

• PDS regime interaction: Section 10 disapplies subsection 1016B(1) for responsible persons in relation to PDS-driven applications for products that are in classes able to be traded on a declared financial market at lodgement. The instrument does not purport to alter other sections of the PDS regime (for example, PDS content obligations, disclosure liabilities or cooling-off rights where set by other sections). Practitioners must therefore assess how s 10’s disapplication sits alongside the broader PDS obligations in the Act.

• No interaction with other statutes expressly mentioned: The instrument contains no cross-references to statutes other than the Act. It therefore does not modify obligations or rights under, for example, the Corporations Regulations, the Australian Securities and Investments Commission Act, the Australian Consumer Law, or financial-sector-specific regimes outside the Act; any such interaction would need to be inferred only where those other regimes refer to the Act’s exposure period provisions.

• Repeal of prior instrument: Schedule 1 repeals ASIC Corporations (Exposure Period) Instrument 2016/74 in its entirety, so any interactions created by that instrument are superseded by the present instrument from commencement (Schedule 1).

In practical terms, the instrument’s interactions are limited: it changes when two specified statutory prohibitions apply, and does so by relying on the Act’s own definitions and administrative structures (declared financial market, ASIC extension powers). It does not purport to displace other statutory duties, nor does it create cross-Act exemptions beyond those expressly set out.

The instrument contains only a short, explicit amendment history as recorded within its text. The relevant items are:

• Instrument details and creation: The instrument is titled ASIC Corporations (Exposure Period) Instrument 2026/90 and was made by Amanda Zeller, delegate of the Australian Securities and Investments Commission, dated 23 March 2026 (front matter and signature block). The instrument is made under subsections 741(1) and 1020F(1) of the Act (s 3).

• Commencement: The instrument commences on the later of the day after it is registered on the Federal Register of Legislation and 1 April 2026 (s 2). The commencement mechanism thus creates a practical earliest effective date of 1 April 2026, subject to the registration timing.

• Repeal of prior instrument: Schedule 1 item 1 explicitly repeals the whole of ASIC Corporations (Exposure Period) Instrument 2016/74. The Schedule specifies “Repeal the instrument.” That is a full repeal rather than a partial amendment, meaning the 2016/74 instrument will not coexist once this instrument commences.

• Sunset / scheduled repeal: The instrument contains a built-in expiry. Section 11 provides that the instrument “is repealed at the start of 1 April 2031.” That creates a five-year maximum life from the earliest statutory commencement date (1 April 2026) unless repealed earlier or replaced.

• No listed amendments: There are no further amendment items or historical modifications recorded within the instrument text. The instrument does not itself schedule any future amendments nor create a mechanism for automatic extension beyond its scheduled repeal date.

• Notes referencing Act transition provisions: The note under s 8 records the Act’s transitional rule that a market previously prescribed under former regulation 1.0.02A of the Corporations Regulations 2001 is taken to be a declared financial market until the first declaration under s 9D(2) of the Act (s 8 note referencing s 1705F). This is not an amendment history item for the instrument, but it is a cross-reference to the Act’s transitional arrangements which affect when the instrument’s exemptions can be engaged in practice.

In short, the instrument replaces the 2016 exposure-period instrument in full, takes effect from registration or 1 April 2026 (whichever is later), and is designed to lapse at the start of 1 April 2031. There is no other internal amendment history recorded in the instrument.

The instrument’s text contains no record of litigation or judicial consideration. There are no cases, determinations, or appeals cited or annexed to the instrument. The instrument itself does not identify any prior judicial interpretations or disputes about its predecessor that would inform its adoption.

Consequently, from the content of this instrument:

• There is no litigation history disclosed or described in the instrument.

• There are no declared precedential matters or rulings that alter how the instrument should be interpreted.

• Any legal challenges or judicial review of actions taken under this instrument would therefore be matters arising after its commencement; the instrument itself contains no reported decisions or litigation outcomes.

Practitioners seeking to anticipate legal risk should therefore treat the instrument as a fresh delegated-law measure without an internal litigation record. Any disputes regarding reliance on the instrument’s exemptions, their factual predicates (for example, whether a class is “quoted” on a declared financial market at the time of lodgement), or the interaction with the Act’s exposure-period regime would be matters for future litigation or administrative review and are not covered by the instrument’s text.

The instrument is concise, but several practical pitfalls arise from its drafting and the way it disapplies the relevant Act provisions. The following are concrete points to watch, grounded in the instrument’s wording:

• The exemptions are narrow and stated in negative form: The instrument repeatedly phrases relief as situations where a person “does not have to comply with” specified subsections of the Act (see ss 7-10). It does not say the Act provision is amended, only that compliance is unnecessary in the narrow factual contexts. That means other obligations under the Act remain in full force.

• Exposure period is a moving target because ASIC can extend it: The instrument’s definition of exposure period includes “the period as extended by ASIC under that subsection” (s 6). If ASIC exercises its extension power before or after lodgement of an updating document, the availability and timing of the s 7 relief can change. Practitioners must therefore check ASIC’s extensions before relying on the timing windows in s 7.

• Section 7(3) preserves s 727(3) as to the original disclosure document: While s 7 creates exemptions in relation to updating documents, it “does not affect the application of subsection 727(3) of the Act to the disclosure document that is being supplemented or replaced” (s 7(3)). In practice, this means parties cannot assume immunity for the original prospectus or disclosure document; practitioners must manage obligations for both the original and updating documents.

• Reliance on quoted/tradable status requires factual certainty at lodgement: Sections 8, 9 and 10 tie relief to the status of a class as quoted or “able to be traded on a declared financial market” at the time of lodgement. That status must be established at the lodgement moment. Section 10(2) clarifies that a present suspension of trading does not disqualify the class, but other factual uncertainties about market status (for example, delisting that takes effect shortly after lodgement, or ambiguous classification of products) create operational risk.

• The instrument does not alter other consumer or disclosure protections: The instrument disapplies s 727(3) and s 1016B(1) in limited circumstances but does not change content obligations, continuous disclosure obligations, or other parts of the Act. Do not treat the exemptions as broad permissions to change disclosure standards or to evade other Act duties.

• Temporal limitation and transitional timing: The instrument’s commencement depends on registration, and it is repealed at the start of 1 April 2031 (ss 2 and 11). Offers that cross the commencement or repeal dates must be carefully assessed for whether the instrument applies.

• The Schedule repeals the 2016 instrument in full: If market participants previously relied on specific drafting or transitional arrangements in the 2016 instrument, those arrangements are now removed and replaced. The instrument does not replicate every aspect of the prior instrument; practitioners must compare texts where continuity is material (Schedule 1).

• The instrument creates a potential mismatch between internal processes and statutory timing: For example, s 7(1) creates a seven-day window after lodgement when an updating document lodged after the exposure period allows dealing. Firms with internal cooling-off procedures, print-and-distribute timetables, or registrar processes must ensure their systems are synchronised to the instrument’s time windows to avoid acting outside the disapplication.

• No express safe harbour or registration-step: The instrument does not require or specify additional steps (such as specific record-keeping or notification) to rely on the exemptions. This absence increases the importance of internal documentation when a firm relies on the instrument: contemporaneous records of the lodgement date, the class status as quoted or tradable at lodgement, and any ASIC extension are the primary evidentiary materials.

These are not hypothetical concerns; they flow directly from the instrument’s textual limits (see especially ss 6-10 and s 7(3)). Practitioners should not assume broader relief than the instrument expressly grants.

Complying with the instrument requires careful fact-checking at defined moments and clear internal processes to document reliance on the exemptions the instrument creates. Practical, source-grounded steps are:

1. Establish whether the instrument applies to your transaction

   • Identify whether the offer involves an updating document lodged under s 719 (s 7), an offer of securities that are in a quoted class (s 8), options over quoted securities (s 9), or a PDS for a product/securities in a class able to be traded on a declared financial market (s 10).
   • Record the lodgement timestamp of disclosure documents, updating documents, and PDSs because the instrument’s relief is fact-specific and time-dependent (see ss 7-10).

2. For updating documents (s 7):

   • If you lodge an updating document after the exposure period for the underlying disclosure document has expired, you may accept applications and issue or transfer securities offered under the updating document until seven days after lodgement (s 7(1)). Record the lodgement date and the seven-day window.
   • If you lodge an updating document before the exposure period expires, you may accept applications, issue or transfer securities after the exposure period ends (s 7(2)). Confirm the exposure period end-date, including any ASIC extension (see s 6).
   • Maintain records showing that s 7(3) was considered and that the original disclosure document’s obligations under s 727(3) remain managed separately (s 7(3)).

3. For quoted securities and options (ss 8-9):

   • Confirm the class is quoted on a declared financial market at the time of lodgement of the disclosure document. Use the market operator’s published records and the Act’s declared financial market framework (s 8 note referencing s 9D and s 1705F).
   • For options, ensure the status is assessed against the underlying securities at the lodgement moment (s 9).
   • Keep documentary evidence of the quoted status as at lodgement, including timestamps from the market operator or the market’s published list of quoted classes.

4. For PDS-driven applications (s 10):

   • If you are a responsible person for a managed investment product or a retail CCIV sub-fund, verify that the product is in a class “able to be traded on a declared financial market” at PDS lodgement (s 10(1)). Note that a current suspension of trading does not negate the class’s status (s 10(2)).
   • Confirm whether the product’s class reasonably satisfies the “able to be traded” threshold, and document the basis for that conclusion (for example, prior trading history, market operator classification).
   • Ensure the PDS meets all other statutory content and delivery obligations; s 10 only disapplies subsection 1016B(1) in the stated circumstances and does not relieve other statutory requirements.

5. Verify ASIC exposure-period extensions and market declarations:

   • Check whether ASIC has extended the exposure period under subsection 727(3) because the instrument’s definition of exposure period includes such extensions (s 6). An ASIC extension can change whether s 7’s windows apply.
   • Confirm the declared financial market status under the Act and any transitional arrangements set out in the Act (s 8 note referencing s 9D and s 1705F).

6. Maintain contemporaneous records:

   • Because the instrument contains no specific procedural safe harbour, keep contemporaneous evidence of lodgement times, market status, internal approvals, and the basis on which a reliance decision was made. This evidence will be material if ASIC queries reliance or if enforcement arises under the Act.

7. Do not assume other obligations are altered:

   • The instrument disapplies particular subsections (ss 727(3) and 1016B(1)) in limited circumstances; it does not change prospectus content, continuous disclosure, licensing, or fiduciary duties. Ensure those obligations continue to be met.

8. Consider operational timelines:

   • Align registrar, transfer agent, and market operations with the instrument’s time windows (for example, the seven-day window under s 7(1)). Adjust internal cut-off times and system workflows to avoid inadvertent dealing outside permitted periods.

9. Plan for the instrument’s lifespan:

   • Note the commencement mechanism (s 2) and the scheduled repeal at the start of 1 April 2031 (s 11). Contracts and offer documents that run beyond repeal should not assume the instrument’s exemptions will continue to be available.

10. Seek legal confirmation for borderline facts:

• Where the quoted or tradable status is unclear, or where exposure-period timing overlaps with ASIC extensions, obtain legal advice and document the reasoning for relying on the instrument.

These compliance steps follow directly from the instrument’s operative text (see ss 2, 6-11). The central compliance hook is factual: establish and document the exact factual predicate at the relevant lodgement time and ensure other statutory obligations under the Act remain satisfied.